About Us
We are a group of scientists and business professionals getting together with an ambition to develop novel medications for neurological diseases including stroke, pain, and addiction by using the deep understanding of opioid receptors.
The name of “Neurokappa” came from the concept that molecules targeting to kappa opioid receptor may have huge drug development values. Some of the existing medications including naloxone, a medication used for opioid overdose rescue. Some of the compounds as kappa opioid receptor agonists have potential therapeutic values in stroke therapy, pain management, depression, and addiction therapy.
Mission
To develop novel compounds targeting opioid receptors for neurological diseases.
Vision
Intranasal administration is an attractive, effective alternative pathway to deliver medications for neurological diseases especially in the out of the hospital settings when intravenous access is not an easy solution
Motto
The efficacy of action should be priority over the mechanism of actions! It is true that the mechanisms of actions may help to discover new indications of an "old" medication. So, we will never stop pursuing both!
Our Team
Portfolio
Salvinorin A and its novel analog
for Stroke
Dezocine and its associated products
for addiction management
Testimonials
Contact Us
Address:
3401 Grays Ferry Ave, Philadelphia, PA 19146
Contact us via Email!
Email:
Renyu Liu, MD, PhD
liur@stroke120.org
John Grothusen, PhD
grothusenj@neurokor.com